-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 17th, the application for marketing authorization of recombinant allosteric human tumor necrosis factor-related apoptosis-inducing ligand ("CPT") for injection submitted by Wuhan Haite Biopharmaceutical Co.
CPT is a new recombinant protein targeting anti-tumor drug developed by its joint-stock subsidiary Beijing Shadong Biotechnology Co.
Phase III clinical trials have shown that CPT combined with TD regimen in the treatment of relapsed and refractory multiple myeloma can significantly improve the progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) of patients.